Researchers have found that cutting off cancer cells from vitamin B2 strips away a defense that helps them escape a lethal form of self-destruction.
That discovery turns a familiar nutrient into a possible pressure point in the fight against tumors.
A hidden survival defense
In cancer cell models, that vulnerability appeared when vitamin B2 no longer shielded the cells from collapse under oxidative stress.
By tracing that failure in the lab, Vera Skafar at the Rudolf Virchow Center (RVZ) connected the cells’ survival directly to riboflavin – the formal name for vitamin B2.
What looked like ordinary nutritional support instead emerged as part of the machinery tumors use to stay alive when threatened.
For treatment research, the key question is no longer whether vitamin B2 matters to cancer cells, but how that protection might be removed without harming the body’s healthy tissues.
Vitamin’s normal job
Outside tumors, vitamin B2 helps cells turn food into usable energy through small chemical helpers used throughout the day.
People get it from common foods such as milk, eggs, meat, spinach, mushrooms, and fortified grains.
In healthy cells, the vitamin helps move chemical charge during the reactions that make energy and support repair.
Cancer creates trouble when the same chemistry strengthens defenses that treatment may need to break at the cellular level.
Cell death trap
A vulnerable tumor cell can die through ferroptosis, an iron-driven cell death that damages fatty membranes from the inside.
During this process, iron helps create harmful membrane damage, and the cell’s outer barriers lose stability from within.
Many tumors raise antioxidant defenses, protections against damaging chemical stress, which slow damage before it reaches a killing point.
That escape makes ferroptosis interesting for cancer therapy, but it also makes the target hard to control safely.
The FSP1 connection
Skafar’s team centered on FSP1, a protein that helps cells keep membrane damage in check during stress.
Riboflavin feeds that protein by helping build a small helper molecule that supports its shape, location, and activity.
When riboflavin levels dropped, FSP1 weakened, and cancer cells became easier to push into ferroptosis under lab conditions.
“Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis, a special form of programmed cell death,” said Skafar.
A bacterial decoy
With no ready blocking drug available, researchers tested roseoflavin, a bacterial compound that resembles vitamin B2 rather than a clinical treatment.
Cancer cells seemed to take up the decoy, then turned it into altered chemical helpers that disrupted FSP1 from inside.
At low concentrations, roseoflavin triggered ferroptosis in cancer cell models, giving the team early proof of concept in the lab.
Laboratory success does not mean a treatment exists, because drugs must still work safely in animals and people through repeated testing.
Promise and caution
For patients, the most important limit is simple: the experiment did not test vitamin restriction as treatment.
Ordinary vitamin B2 supports healthy tissues, and deficiency can harm the body long before it hurts tumors across daily life.
A future therapy would need to hit tumor chemistry more precisely than a diet ever could.
That distinction keeps the finding useful without turning nutrition into a risky home experiment for patients outside the clinic.
Beyond cancer cells
Ferroptosis also matters outside cancer medicine because excess membrane damage can injure nerves and transplanted organs after injury.
In those settings, blocking cell death may help protect tissue rather than destroy dangerous cells during illness or surgery.
Cancer treatment points in the opposite direction, where doctors may want selected cells to lose protection while sparing nearby healthy cells.
One mechanism can therefore demand two different strategies, depending on whether cell death causes harm or healing in each disease.
Funding the chase
Europe has already put serious money behind this search for ways to control ferroptosis in difficult cancers.
A European project began in May 2024 and carries nearly two million euros in funding over five years.
That investment supports the hunt for drugs that can expose tumor cells to this death pathway in future experiments.
Money cannot guarantee a medicine, but it can move a promising cell finding into preclinical tests – studies done before human trials.
Nutrients cut both ways
Vitamin B2 now joins a growing list of ordinary nutrients with complicated roles inside diseased cells.
Cells do not label chemistry as good or bad; they use whatever helps them survive inside every living cell.
For tumors, a protective pathway can become a liability when scientists learn how to interrupt it at the right moment.
For the public, this finding supports the need for targeted drugs, not fear of a basic nutrient.
Future treatment steps
The findings connect diet chemistry, tumor survival, and controlled cell death through one targetable protective route for cancer therapy.
Next, scientists must build better blockers and test in rigorous models whether tumors can be hit without weakening healthy tissue.
The information was obtained from a University of Würzburg press release.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap , a free app brought to you by Eric Ralls and Earth.com.
—–